PCSK9 Inhibitors in the Progression of Aortic Stenosis

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 140 participants.

Also called NCT03051360

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 2
Enrolled
  • 140 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03051360
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03051360. Randomized; quadruple masking; primary purpose prevention. Start 2017-06-01 (anticipated); primary completion 2019-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
PCSK9 Inhibitors in the Progression of Aortic Stenosis
Condition
Aortic Valve Stenosis
Intervention (Drug)
PCSK9 Inhibitor [EPC]
Intervention (Drug)
Placebos
Lead sponsor
Seoul National University Hospital (class: other)

Record details

Record id
cardio:ct-nct03051360
Content hash
79a879e80445c7f0122b4f82c7d8e6bf4c0b03ba42124027b4d06f55bd0e4ebd